

SUPPLEMENT

Quantifying absolute treatment effect heterogeneity for time-to-event outcomes across different risk strata: divergence of conclusions with risk difference and restricted mean survival difference

Carolien C.H.M. Maas^{1, 2, 3}, David M. Kent³, Avinash G. Dinmohamed^{1, 2}, David van Klaveren^{1, 3}

¹Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands

²Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands

³Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA

Corresponding author

Carolien C.H.M. Maas, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, Netherlands, c.h.m.maas@erasmusmc.nl

Supplemental Information. Relationship between the risk difference (RD), relative risk (RR), and hazard ratio (HR) in time-to-event data.

Definitions

Mortality probability $p(t) = P(T \leq t)$ represents the probability that a subject will die before time t .

Risk difference $RD = p(t|control) - p(t|treated)$ is the difference in survival probabilities between the treated and control groups at time t .

Relative risk $RR = \frac{p(t|treated)}{p(t|control)}$ is the ratio of the mortality probabilities between the treated and control groups at time t .

Hazard ratio $HR = \frac{h(t|treated)}{h(t|control)}$ is the ratio of hazards between the treated and control groups at time t .

Constant HR

When the HR is constant, $h(t) = H(t)$.

$$\text{Thus, } HR = \frac{h(t|treated)}{h(t|control)} = \frac{H(t|treated)}{H(t|control)} = \frac{-\ln(S(t|treated))}{-\ln(S(t|control))} = \frac{\ln(s(t|treated))}{\ln(s(t|control))} = \frac{\ln(1-p(t|treated))}{\ln(1-p(t|control))}$$

$$\text{Thus, } p(t|treated) = 1 - (1 - p(t|control))^{HR}$$

$$\text{Therefore, } RD = p(t|control) - 1 + (1 - p(t|control))^{HR}$$


$$\text{And } RR = \frac{1 - (1 - p(t|control))^{HR}}{p(t|control)}$$

Supplemental Table 1. Detailed description of the randomized clinical trials and performance metrics of their internally developed risk model.


	SOLVD Prevention	SOLVD Intervention
Year ¹	1992 ¹	1991 ¹
Patient population	Congestive heart failure	Congestive heart failure
Treatment	Enalapril versus placebo	Enalapril versus placebo
N ²	Prevention: 4,228	Intervention: 2,569
Outcome	Death or hospitalization due to heart failure	All-cause mortality
Follow-up ³	3.1 [2.2; 4.0]	3.5 [2.9; 4.0]
90 th percentile ⁴	4.6	4.3
KM ⁵	69.5 [67.4; 71.6]	54.5 [51.7; 57.4]
RD	0.03 [-0.01; 0.07]	0.03 [-0.02; 0.09]
p-value ⁶	0.001	0.009
ΔRMST	0.16 [0.08; 0.25]	0.18 [0.06; 0.29]
Predictors	Age, blood urea nitrogen, NYHA heart failure class, diuretic therapy, sex, race, history of CABG or other cardiac surgery, history of chronic obstructive pulmonary disease, history of atrial fibrillation, SBP, DBP, heart rate, ACE inhibitor therapy, beta blocker therapy, creatinine, potassium, white blood cell count ²⁻⁴	Age, sex, body weight, heart rate, current smoking status, history of diabetes, history of MI, history of oedema, history of chronic obstructive pulmonary disease, NYHA heart failure class, left ventricular ejection fraction, history of atrial fibrillation ACE inhibitor therapy, beta blocker therapy, creatinine, SBP, DBP, sodium, blood urea nitrogen ⁵⁻⁸
C-index	0.65	0.67

¹Year of publication with references; ²Sample size for patients with an outcome recorded; ³Median [IQR] follow-up time calculated using reverse Kaplan-Meier estimates; ⁴90th percentile of follow-up time using reverse Kaplan-Meier estimates. ⁵KM is the Kaplan-Meier estimate at the 90th percentile of follow-up time with a 95% confidence interval; ⁶p-value of the log-rank test to test if the treatment-stratified Kaplan-Meier curves truncated at 90th percentile of follow-up time were significantly different. Abbreviations: ACE = angiotensin-converting-enzyme; CABG = coronary artery bypass graft; DBP = diastolic blood pressure; NYHA = New York Heart Association; MI = myocardial infarction; SBP = systolic blood pressure, ΔRMST = difference in restricted mean survival time.


Supplemental Figure 1. Illustration using artificial data: the difference in restricted mean survival time (Δ RMST) and risk difference (RD) give a similar pattern of absolute treatment effect across risk strata. Simulated the event times of 1,000,000 individuals in four risk strata using an increasing failure rate, a constant overall proportional HR for treatment of 0.5, an average overall event rate of 10%, 30%, and 50% among the control group, and a discriminative ability of the risk-stratified model of 0.60, 0.75, and 0.90. The red highlighted panels indicate where RD and Δ RMST provide discordant treatment targeting.



Supplemental Figure 2. Illustration using artificial data: the difference in restricted mean survival time (Δ RMST) and risk difference (RD) give a similar pattern of absolute treatment effect across risk strata. Simulated the event times of 1,000,000 individuals in four risk strata using a constant failure rate, a constant overall proportional HR for treatment of 0.8, an average overall event rate of 10%, 30%, and 50% among the control group, and a discriminative ability of the risk-stratified model of 0.60, 0.75, and 0.90. The red highlighted panels indicate where RD and Δ RMST provide discordant treatment targeting.



Supplemental Figure 3. Illustration using artificial data: the difference in restricted mean survival time (Δ RMST) and risk difference (RD) give a similar pattern of absolute treatment effect across risk strata. Simulated the event times of 1,000,000 individuals in four risk strata using a constant failure rate, a constant overall proportional HR for treatment of 0.5, an average overall event rate of 10%, 30%, and 50% among the control group, and a discriminative ability of the risk-stratified model of 0.60, 0.75, and 0.90. The red highlighted panels indicate where RD and Δ RMST provide discordant treatment targeting.



References

1. Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Jr., Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992; **327**: 685-91.
2. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *J Am Coll CRDiol* 2008; **52**: 347-56.
3. O'Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). *Am Heart J* 2008; **156**: 662-73.
4. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. *Circulation* 2006; **113**: 1424-33.
5. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW. Predicting mortality in patients with heart failure: a pragmatic approach. *Heart* 2003; **89**: 605-9.
6. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. *Jama* 2003; **290**: 2581-7.
7. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. *Eur Heart J* 2006; **27**: 65-75.
8. Senni M, Santilli G, Parrella P, et al. A novel prognostic index to determine the impact of cRDiac conditions and co-morbidities on one-year outcome in patients with heart failure. *Am J CRDiol* 2006; **98**: 1076-82.